Pharmacogenetics of Response to GLP1R Agonists

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before and after administration of drug). 2. Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs (before and after administration of drug). Genotyping will be conducted using a high-density array with comprehensive coverage of DNA sequence variants. In addition, the analysis will leverage a global imputation panel generated from 1,025 Amish individuals.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 89
Healthy Volunteers: t
View:

• BMI greater than or equal to 27 kg/m2

• Of Amish Descent

Locations
United States
Pennsylvania
Amish Research Clinic
RECRUITING
Lancaster
Contact Information
Primary
Amber L Beitelshees, PharmD
abeitels@som.umaryland.edu
(410)706-0118
Backup
Simeon I Taylor, MD, PhD
staylor2@som.umaryland.edu
(410)706-6439
Time Frame
Start Date: 2022-04-11
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 600
Treatments
Experimental: Open label administration of semaglutide
Semaglutide: 0.25 mg, sc, q.week for 4 weeks followed by 0.5 mg, sc, q.week for 2 weeks
Related Therapeutic Areas
Sponsors
Leads: University of Maryland, Baltimore

This content was sourced from clinicaltrials.gov